Literature DB >> 9165443

Early innominate osteotomy as a treatment for avascular necrosis complicating developmental hip dysplasia.

E Bar-On1, M H Huo, P A DeLuca.   

Abstract

The clinical and radiographic outcomes of 25 patients with avascular necrosis (AVN) of the femoral head complicating developmental hip dysplasia (DDH) were analyzed. Seven patients (group A) had an innominate osteotomy 1-3 years after the ischemic insult. Eight patients (group B) had a pelvic osteotomy between 5 and 10 years after the insult, and 10 patients (group C) did not have a pelvic osteotomy. The minimum follow-up period was 10 years from the time of the ischemic insult. The hips in group A patients (early osteotomy) showed significantly better radiographic outcomes as assessed by a modified Severin grading. These patients also had less pain, fewer gait disturbances, and required fewer additional procedures for limb length discrepancy or greater trochanteric overgrowth.

Entities:  

Mesh:

Year:  1997        PMID: 9165443     DOI: 10.1097/01202412-199704000-00010

Source DB:  PubMed          Journal:  J Pediatr Orthop B        ISSN: 1060-152X            Impact factor:   1.041


  3 in total

1.  Osteonecrosis complicating developmental dysplasia of the hip compromises subsequent acetabular remodeling.

Authors:  Andreas Roposch; Deborah Ridout; Evangelia Protopapa; Nicholas Nicolaou; Yael Gelfer
Journal:  Clin Orthop Relat Res       Date:  2013-01-26       Impact factor: 4.176

2.  Natural history of type III growth disturbance after treatment of developmental dislocation of the hip.

Authors:  Claudio A Fernandez; Lori A Dolan; Stuart L Weinstein; Jose A Morcuende
Journal:  Iowa Orthop J       Date:  2008

3.  Patient-reported outcomes in young adults with osteonecrosis secondary to developmental dysplasia of the hip - a longitudinal and cross-sectional evaluation.

Authors:  Avi Marks; Mario Cortina-Borja; Dror Maor; Aresh Hashemi-Nejad; Andreas Roposch
Journal:  BMC Musculoskelet Disord       Date:  2021-01-07       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.